NCT02743806

Who might be able to join this trial:

• You previously received vedolizumab (not a placebo or comparison drug) as part of an earlier qualifying clinical study.
• Your doctor believes you are still benefiting from vedolizumab and that continuing it is important, either because there is no similar alternative available to you, or because stopping treatment could cause your condition to get worse.
• If you are a man who is not sterilized and is sexually active with a woman who could become pregnant, you agree to use reliable contraception from the start of the study until 18 weeks after your last dose.
• If you are a woman who could become pregnant and are sexually active with a man who is not sterilized, you agree to use reliable contraception from the start of the study until 18 weeks after your last dose.

Who may not be able to join:

• Vedolizumab is already available to you through normal commercial means, such as through insurance or other reimbursement programs.
• You have a medical condition or have had a previous treatment that your doctor believes would make it unsafe or unsuitable for you to participate in this study.
• If you are a woman who is currently pregnant, breastfeeding, or planning to become pregnant or donate eggs during the study or within 18 weeks after your last dose.
• If you are a man who plans to donate sperm during the study or within 18 weeks after your last dose.
• You have received a live vaccine in the past 18 weeks, or you will need a live vaccine during the study or within 18 weeks after your last dose.

Important: Always verify eligibility with the trial site directly before applying.